Aggregated cardiovascular risk scores as a marker of neuropathy among patients with type 2 diabetes - A correlational analysis
Vijayananth P, Anbarasi M, Hemadharshini S, Tharun S
Keywords :
microvascular, neuropathy, type 2 diabetes mellitus
Citation Information :
P V, M A, S H, S T. Aggregated cardiovascular risk scores as a marker of neuropathy among patients with type 2 diabetes - A correlational analysis. 2017; 5 (2):5-9.
Background: Diabetes is a metabolic disorder wherein the ensuing complications contribute to the morbidity and mortality to a major extent. According to the ticking-dock hypothesis, macrovascular complications like cardiovascular problems develop in the pre-diabetic stage in type 2 diabetes whereas microvascular complications are slower to develop. Recent studies suggest that besides hyperglycemia, many other vascular risk factors are also involved in the aetiology of neuropathy.
Aim:: This study aimed to predict the risk of developing neuropathy from the cardiovascular risk factors in patients with type 2 diabetes.
Materials and Methods: This cross-sectional study was carried out at Dhanalakshmi Srinivasan Medical College Hospital, Perambalur. 102 biochemically proven type 2 diabetic patients, were included in the study by convenient sampling technique following specific inclusion and exclusion criteria. Data on demographics, duration of diabetes, nature of treatment and family history were collected; blood pressure was recorded in the dominant arm and the subjects were subjected to fasting and post-prandial blood sugars and lipid profile estimations. Neurological examination was performed to assess the risk of neuropathy using Michigan Neuropathy Screening Instrument (MNSI). Using the patients' examination and investigation reports, the cardiovascular risk scores were computed by Framingham Heart Risk Score. Correlation was sought between the MNSI symptom and sign scores and FHRS using Spearman Rank Correlation Test.
Results: While the symptom scores of MNSI did not significantly correlate with the FHRS (r=0.04; p=0.64), the MNSI sign scores showed a significant positive correlation with the latter correlation (r =0.197; p=0.04), the correlation coefficient however was weak. Conclusions: As this study showed only very weak correlation between the aggregated cardiovascular risk scores, it is not conclusive to be used as a marker for assessing the risk of neuropathy at the earliest stage in diabetes, even when other risk factors namely, duration of diabetes, glycaemic status, BMI, hypertension and lipid profile were inconclusively associated.
Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. 2006 Feb;29(2):340-4.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39.
Tesfaye S, Chaturvedi N, Eaton S, Ward J, Fuller J. Cardiovascular Risk Factors Predict The Development Of Diabetic Peripheral Neuropathy. J Peripher Nerv Syst. 2000 Sep 1;5(3):175-175.
Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012 Jul;29(7):937-44.
Feldman EL, Stevens MJ. Clinical testing in diabetic peripheral neuropathy. Canadian Journal of Neurological Sciences. 1994 Nov;21(S4):S3-7.
Owolabi MO, Ipadeola A, Adeleye JO. Aggregate Cardiovascular Risk Is a Stronger Statistical Correlate of Clinically Evident Diabetic Peripheral Neuropathy Than HbA lc Alone. J Natl Med Assoc. 2010;102(8).
Lloyd-Jones DM, Wilson PWF, Larson MG, Beiser A, Leip E, D'Agostino RB, Levy D.. Framingham Risk Score and Prediction of Lifetime Risk for Coronary Heart Disease. Am J Cardiol. 2004;94:20-4.
May O, Arildsen H, Damsgaard EM, Mickley H. Cardiovascular autonomic neuropathy in insulin-dependent diabetes mellitus: prevalence and estimated risk of coronary heart disease in the general population. Journal of Internal Medicine. 2000 Dec 1;248(6):483-91.
Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. The Lancet. 2012 Jun 22;379(9833):2279-90.
Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, lonescu-Tirgoviste C, et al. Vascular Risk Factors and Diabetic Neuropathy. N Engl J Med. 2005 Jan 27;352(4):341-50.
Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, et al. Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care. 2013 May 1;36(5):1193-9.
Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab. 2016;20(4):546-51.